Charlotte, N.C.-based Dentsply Sirona reported $898 million in net sales for the second quarter of 2026, a 4.1% decline from $936 million in the same period last year, according to an Aug. 6 earnings release.
Net income attributable to Dentsply Sirona was $37 million, compared to a net loss of $45 million in Q2 2025. Adjusted EBITDA was $190 million, down slightly from $197 million in Q2 2025.
The steepest decline in net sales came from the company’s Orthodontic and Implant Solutions segment, which fell 13.2% to $197 million. Essential Dental Solutions declined 2.7% to $376 million, while Connected Technology Solutions fell 1.5% to $239 million. Wellspect Healthcare rose 7.1% to $86 million.
Operating cash flow improved from $48 million in Q2 2025 to $99 million in Q2 2026, aided by approximately $44 million in tariff refunds. The company also repurchased 1.3 million shares for $12 million during the quarter, and held $239 million in cash as of June 30.
Dentsply Sirona maintained its full-year 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
President and CEO Dan Scavilla said the company is making “meaningful progress” in several high priority areas as it executes its Return-to-Growth Action plan. The action plan was launched in November to position the company for sustainable growth over the next 24 months.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place September 14-15 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
